ConductScience.org, home

Paper41375007

Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.

Salfi G and 14 others. Cancers (Basel), 2025. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations. Papers, record 41375007. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41375007

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Predicting Toxicities and Survival Outcomes in De Novo Metastatic Hormone-Sensitive Prostate Cancer Using Clinical Features, Routine Blood Tests and Their Early Variations.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2025
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2025-12-14
PubMed

Authors15

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Salfi GGiuseppehttps://orcid.org/0000-0003-4953-0339
2Pedrani MMartinohttps://orcid.org/0000-0002-8502-8226
3Colombo AAmoshttps://orcid.org/0009-0000-3638-8973
4Ruinelli LLorenzohttps://orcid.org/0000-0002-9144-2570
5Brenna DDanielehttps://orcid.org/0000-0001-8742-935X
6Clerici CMAChiara Maria Agrippina
7Pecoraro GGiovannahttps://orcid.org/0009-0003-6743-6933
8Merler SSarahttps://orcid.org/0000-0002-8691-6284
9Erhart CCCaroline-Claudia
10Puglisi MMarialuisa
11Turco FFabio
12Tortola LLuigi
13Vogl UUrsulahttps://orcid.org/0000-0002-2046-4246
14Gillessen SSilkehttps://orcid.org/0000-0001-5746-6555
15Pereira Mestre RRicardohttps://orcid.org/0000-0002-3123-3697

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References39

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
139521639Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216.Eur Urol Oncol2025https://conductscience.org/library/papers/39521639PubMed
220888271Serum alkaline phosphatase changes predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy.Urol Oncol2012https://conductscience.org/library/papers/20888271PubMed
319399748Review of major adverse effects of androgen-deprivation therapy in men with prostate cancer.Cancer2009https://conductscience.org/library/papers/19399748PubMed
438688773EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer.Eur Urol2024https://conductscience.org/library/papers/38688773PubMed
531843335
Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate plus Prednisone or Placebos Added to Androgen Deprivation Therapy: Post Hoc Analysis of Phase 3 LATITUDE Study.
Eur Urol2020https://conductscience.org/library/papers/31843335PubMed
610737287Clinical survival predictors in patients with advanced cancer.Arch Intern Med2000https://conductscience.org/library/papers/10737287PubMed
739279580Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial.J Clin Oncol2024https://conductscience.org/library/papers/39279580PubMed
830477464Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival?BMC Cancer2018https://conductscience.org/library/papers/30477464PubMed
933058693Machine Learning in Oncology: Methods, Applications, and Challenges.JCO Clin Cancer Inform2020https://conductscience.org/library/papers/33058693PubMed
1029339044The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.Clin Genitourin Cancer2018https://conductscience.org/library/papers/29339044PubMed
1117997442Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.J Urol2008https://conductscience.org/library/papers/17997442PubMed
1236682938Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.Eur Urol Oncol2023https://conductscience.org/library/papers/36682938PubMed
1319097774New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer2009https://conductscience.org/library/papers/19097774PubMed
1433866442Cardiovascular Toxicities of Androgen Deprivation Therapy.Curr Treat Options Oncol2021https://conductscience.org/library/papers/33866442PubMed
1529475737Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.Eur Urol2018https://conductscience.org/library/papers/29475737PubMed
1639641119Treatment-related Hypertension as a Prognostic Factor for De Novo Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Real-world Evidence Study.Eur Urol Open Sci2025https://conductscience.org/library/papers/39641119PubMed
1728899723Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease.Clin Genitourin Cancer2017https://conductscience.org/library/papers/28899723PubMed
1831150574Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.N Engl J Med2019https://conductscience.org/library/papers/31150574PubMed
1931092914A new era: artificial intelligence and machine learning in prostate cancer.Nat Rev Urol2019https://conductscience.org/library/papers/31092914PubMed
2029261442Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.J Clin Oncol2018https://conductscience.org/library/papers/29261442PubMed

See all 39 referencesDownload CSV of references

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ALB213PubTator's text mininghttps://conductscience.org/library/genes/213NCBI Gene
NPEPPS9520PubTator's text mininghttps://conductscience.org/library/genes/9520NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41375007

GET https://conductscience.org/api/papers/v1/41375007/references?page=2